##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 9 (2025)

Outcomes in patients with abdominal soft tissue sarcoma: a retrospective cohort study from a single Swiss tertiary referral centre

Cite this as:
Swiss Med Wkly. 2025;155:4091
Published
25.09.2025

Summary

STUDY AIMS: Abdominal and retroperitoneal sarcomas are rare and heterogeneous. Despite a considerable number of sarcoma centres in Switzerland, only very limited data is available regarding clinical outcomes after primary surgical treatment. In this study, we retrospectively analysed a cohort of 157 patients treated at a Swiss sarcoma centre, aiming to assess whether the clinical outcomes in our cohort are comparable to those reported by international centres.

METHODS: Overall, 271 patients with abdominal and retroperitoneal sarcomas, treated between January 2012 and December 2022, were available. Patients with malignant disease and primary resection were included. The primary endpoint was overall survival, while secondary endpoints included disease-free survival, incidence of histological subtypes, completeness of surgical resection and tumour rupture.

RESULTS: Ultimately 157 patients with primary, resectable soft tissue sarcoma were included in the analysis. Median follow-up after surgery was 52.6 months (95% confidence interval [CI]: 42.24–62.95). Median overall survival was 87.9 months (95% CI: 54.95–120.74); by subgroup, 117.5 months for gastrointestinal stroma tumour (95% CI: 76.96–158.00), 61.8 months for liposarcoma (95% CI: 40.16–83.36), 117.8 months for leiomyosarcoma (95% CI not achieved) and 100.2 months for other rare subtypes (95% CI: 59.65–111.30). Forty-four (28%) patients developed tumour recurrence.

CONCLUSIONS: Overall outcomes in this series are comparable to those from large international registries. A national data registry might help to improve reporting of clinical data and assure quality of care of Swiss sarcoma patients.

 

 

References

  1. 1. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases. Int J Cancer. 2006 Dec;119(12):2922–30. 10.1002/ijc.22239
  2. 2. Gounder MM, Agaram NP, Trabucco SE, Robinson V, Ferraro RA, Millis SZ, et al. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nat Commun. 2022 Jun;13(1):3406. 10.1038/s41467-022-30496-0
  3. 3. Kollár A, Rothermundt C, Klenke F, Bode B, Baumhoer D, Arndt V, et al.; NICER Working Group. Incidence, mortality, and survival trends of soft tissue and bone sarcoma in Switzerland between 1996 and 2015. Cancer Epidemiol. 2019 Dec;63:101596. 10.1016/j.canep.2019.101596
  4. 4. Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, et al.; ESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: clinicalguidelines@esmo.org. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021 Nov;32(11):1348–65. 10.1016/j.annonc.2021.07.006
  5. 5. Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg. 2014 Sep;260(3):416–21. 10.1097/SLA.0000000000000869
  6. 6. Swallow CJ, Strauss DC, Bonvalot S, Rutkowski P, Desai A, Gladdy RA, et al.; Transatlantic Australasian RPS Working Group (TARPSWG). Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. Ann Surg Oncol. 2021 Nov;28(12):7873–88. 10.1245/s10434-021-09654-z
  7. 7. Bonvalot S, Gaignard E, Stoeckle E, Meeus P, Decanter G, Carrere S, et al. Survival Benefit of the Surgical Management of Retroperitoneal Sarcoma in a Reference Center: A Nationwide Study of the French Sarcoma Group from the NetSarc Database. Ann Surg Oncol. 2019 Jul;26(7):2286–93. 10.1245/s10434-019-07421-9
  8. 8. Berger NG, Silva JP, Mogal H, Clarke CN, Bedi M, Charlson J, et al. Overall survival after resection of retroperitoneal sarcoma at academic cancer centers versus community cancer centers: An analysis of the National Cancer Data Base. Surgery. 2018 Feb;163(2):318–23. 10.1016/j.surg.2017.07.009
  9. 9. Willburger JC, von Strauss M, Peterson CJ, Glass TR, Kettelhack C. Incidence, Treatment and Outcome of Patients with Retroperitoneal Soft-Tissue Sarcoma in Switzerland 2005-2015: A Population-Based Analysis. World J Surg. 2022 Feb;46(2):461–8. 10.1007/s00268-021-06374-z
  10. 10.Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica. 2021 Apr;113(2):70–84. 10.32074/1591-951X-213
  11. 11. Coindre JM. Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med. 2006 Oct;130(10):1448–53. 10.5858/2006-130-1448-GOSTSR
  12. 12. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006 May;23(2):70–83. 10.1053/j.semdp.2006.09.001
  13. 13. Anaya DA, Lahat G, Liu J, Xing Y, Cormier JN, Pisters PW, et al. Multifocality in retroperitoneal sarcoma: a prognostic factor critical to surgical decision-making. Ann Surg. 2009 Jan;249(1):137–42. 10.1097/SLA.0b013e3181928f2f
  14. 14. Chen Y, Hao J, Yang Y, Yang J, Hao X. Tumor rupture predicts early metastasis and poor prognosis in stage III soft tissue sarcomas. World J Surg. 2011 May;35(5):1002–9. 10.1007/s00268-011-0995-9
  15. 15. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205–13. 10.1097/01.sla.0000133083.54934.ae
  16. 16. Honoré C, Méeus P, Stoeckle E, Bonvalot S. Soft tissue sarcoma in France in 2015: Epidemiology, classification and organization of clinical care. J Visc Surg. 2015 Sep;152(4):223–30. 10.1016/j.jviscsurg.2015.05.001
  17. 17. Dashti NK, Cates JM. Risk Assessment of Visceral Sarcomas: A Comparative Study of 2698 Cases from the SEER Database. Ann Surg Oncol. 2021 Oct;28(11):6852–60. 10.1245/s10434-020-09576-2
  18. 18. Group EE; ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25 Suppl 3:iii21–6. 10.1093/annonc/mdu255
  19. 19. Ducimetière F, Lurkin A, Ranchère-Vince D, Decouvelaere AV, Péoc’h M, Istier L, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6(8):e20294. 10.1371/journal.pone.0020294
  20. 20. Dirnhofer S, Leyvraz S. Current standards and progress in understanding and treatment of GIST. Swiss Med Wkly. 2009 Feb;139(7-8):90–102. 10.4414/smw.2009.12166
  21. 21. Bucher P, Egger JF, Gervaz P, Ris F, Weintraub D, Villiger P, et al. An audit of surgical management of gastrointestinal stromal tumours (GIST). Eur J Surg Oncol. 2006 Apr;32(3):310–4. 10.1016/j.ejso.2005.11.021
  22. 22. Krajinovic K, Germer CT, Agaimy A, Wünsch PH, Isbert C. Outcome after resection of one hundred gastrointestinal stromal tumors. Dig Surg. 2010;27(4):313–9. 10.1159/000280022
  23. 23. Bucher P, Villiger P, Egger JF, Buhler LH, Morel P. Management of gastrointestinal stromal tumors: from diagnosis to treatment. Swiss Med Wkly. 2004 Mar;134(11-12):145–53. 10.4414/smw.2004.10530
  24. 24. Bonvalot S, Cozic N, Le Cesne A, Blay JY, Penel N, Fau M, et al. ASO Visual Abstract: Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial. Ann Surg Oncol. 2023;30(13):8671–2. 10.1245/s10434-023-14396-1
  25. 25. Gronchi A, Miceli R, Shurell E, Eilber FC, Eilber FR, Anaya DA, et al. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol. 2013 May;31(13):1649–55. 10.1200/JCO.2012.44.3747
  26. 26. Gronchi A, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, et al. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group. Ann Surg. 2016 May;263(5):1002–9. 10.1097/SLA.0000000000001447
  27. 27. Bonvalot S, Gronchi A, Le Péchoux C, Swallow CJ, Strauss D, Meeus P, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020 Oct;21(10):1366–77. 10.1016/S1470-2045(20)30446-0
  28. 28. Derbel O, Heudel PE, Cropet C, Meeus P, Vaz G, Biron P, et al. Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort). PLoS One. 2017 Feb;12(2):e0158406. 10.1371/journal.pone.0158406